The company is set to launch the first US spot LINK ETF this week. Grayscale plans to convert its existing LINK trust into an ETF. LINK price remains under pressure amid broader bearishness. The cryptocurrency market is trading in the red on Monday, with the value of all digital tokens down by 5% the past […] The post Grayscale to launch first US spot Chainlink ETF through Trust conversion appeared first on CoinJournal.The company is set to launch the first US spot LINK ETF this week. Grayscale plans to convert its existing LINK trust into an ETF. LINK price remains under pressure amid broader bearishness. The cryptocurrency market is trading in the red on Monday, with the value of all digital tokens down by 5% the past […] The post Grayscale to launch first US spot Chainlink ETF through Trust conversion appeared first on CoinJournal.

Grayscale to launch first US spot Chainlink ETF through Trust conversion

  • The company is set to launch the first US spot LINK ETF this week.
  • Grayscale plans to convert its existing LINK trust into an ETF.
  • LINK price remains under pressure amid broader bearishness.

The cryptocurrency market is trading in the red on Monday, with the value of all digital tokens down by 5% the past day to $2.94 trillion.

While risk-off mood dominates the landscape, Grayscale Investment is preparing to debut the first US spot Chainlink exchange-traded fund.

ETF expert Nate Gerace expects the product to arrive this week, marking a crucial milestone for Chainlink and the overall altcoin ETF sector.

Notably, Grayscale will create this ETF by converting and up-listing its existing Chainlink Trust, offering traditional investors compliant access to Chainlink.

Meanwhile, this adds to the latest wave of altcoin ETF launches in the United States.

We have had multiple altcoin ETFs, including XRP and Dogecoin, since Solana, Hedera, and Litecoin kick-started the wave in late October.

Now, the first spot LINK ETF is set to debut in the United States this week, reflecting demand for these products despite the broader market turmoil.

A spot exchange-traded fund holds LINK assets instead of derivatives, offering individuals direct and regulated exposure to Chainlink as an investment vehicle.

That’s crucial in cementing Chainlink’s legitimacy among traditional investors, many of whom have ignored crypto due to the associated complexities.

Indeed, a LINK ETF alleviates the need for private keys, wallets, and off-exchange asset storage.

The fund will open Chainlink to individuals who prefer the safety of traditional retirement and brokerage accounts.

The strategic conversion

Grayscale took a notable approach, converting a private trust into an exchange-traded fund.

The strategy has crucial benefits.

First and foremost, the LINK ETF will meet an in-built investor base as trust holders access a more liquid ETF model.

Also, the approach streamlines valuation and custody as the trust already has LINK assets.

Lastly, the move eases regulatory challenges as the trust adheres to compliant standards.

Chainlink exhibits substantial selling pressure today.

It has lost more than 6% of its value after a sudden dip on the daily chart, fueled by a broader market crash.

LINK is trading at $12.16, with a 125% uptick in daily trading volume reflecting increased activity from participants, possibly reducing exposure to avoid further losses.

Sellers target the nearest support zone at $11 and $9.8 amid intensified declines.

Failure to hold $8.20 – $8.50 would catalyze deeper slides to $6.80 – $7.20.

On the other hand, bulls should reclaim and defend $13.

Steadying above $15.50 will likely trigger buyer resurgence and stable momentum.

LINK can rally to $19, then $23, and clear the path to $30.

However, prevailing conditions suggest short-term struggles before LINK establishes a decisive directional bias.

The post Grayscale to launch first US spot Chainlink ETF through Trust conversion appeared first on CoinJournal.

Market Opportunity
Intuition Logo
Intuition Price(TRUST)
$0.1092
$0.1092$0.1092
-2.58%
USD
Intuition (TRUST) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26